For the first time, a study in The New England Journal of Medicine is comparing the most popular drugs for weight loss, Zepbound and Wegovy. NBC News medical contributor Dr. Natalie Azar joins TODAY to break down the results and the differences in the medications.
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink Partners said confirm the GLP-1 drug’s edge in the closely watched market race.
In adults with obesity but not diabetes, tirzepatide leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. Medscape Medical News
As WeightWatchers files for bankruptcy, we examine the competition it faces from weight loss jabs.
Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision to declare the end of the shortage of Novo Nordisk’s semaglutide, Judge Mark Pittman agreed that Eli Lilly’s tirzepatide is in sufficient supply, meaning compounding pharmacies can no longer sell the lucrative weight loss drugs.
WeightWatchers (WW) announced Tuesday that it is filing for bankruptcy in an attempt to crawl out of more than $1 billion in debt. The move comes as the company refocuses on prescribing weight loss GLP-1 drugs like Ozempic.Read more…
PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ — Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on…
(MedPage Today) — Note that some links may require registration or subscription. MedPage Today is collecting stories of HHS staffers across all agencies affected by Trump administration cuts. If you want to share your story, please email MPT_Editorial…
Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide—a drug known as Zepbound—on weight loss with respect to energy expenditure, fat oxidation and calorie intake.
